Heminevrin

Heminevrin is an oral prescription medication whose active ingredient is clomethiazole. It is supplied without a specified brand name, strength, or dosage form, and is marketed in the European Union. Clomethiazole belongs to the sedative‑hypnotic class and acts as a positive allosteric modulator of the G‑protein‑linked GABA‑A receptor, producing central nervous system depression. The product is used under medical supervision for specific and therapeutic conditions.

Heminevrin (clomethiazole) is indicated for the short‑term management of certain central nervous system conditions under physician direction.

- Acute alcohol withdrawal syndrome, particularly when rapid symptom control is required. - Short‑term treatment of severe insomnia when other therapies are ineffective. - Adjunctive therapy in hospitalised patients undergoing detoxification from alcohol dependence. - Situations where a rapid‑acting sedative‑hypnotic is preferred over benzodiazepines. - Management of agitation and tremor associated with severe alcohol withdrawal. - Short‑duration sedation for diagnostic procedures in patients with a history of alcohol dependence.

The pharmacologic activity of clomethiazole can produce a range of adverse effects, which are generally categorized by frequency and severity. Patients should be monitored for both expected and unexpected reactions during therapy.

Common: - Drowsiness or somnolence. - Dizziness or light‑headed feeling. - Headache. - Nausea or mild gastrointestinal discomfort. - Dry mouth or altered taste. - Visual disturbances such as blurred vision. - Mild confusion or difficulty concentrating.

Serious: - Respiratory depression, especially when combined with other depressants. - Severe hypotension or cardiovascular collapse. - Paradoxical agitation or seizures in rare cases. - Hepatic dysfunction indicated by elevated liver enzymes. - Allergic reactions including rash, pruritus, or angioedema. - Cardiac arrhythmias in patients with pre‑existing heart disease.

When prescribing Heminevrin, clinicians should consider several precautionary measures to minimise risk and ensure safe use.

- Assess liver and kidney function before initiating therapy. - Use the lowest effective dose for the shortest duration required. - Avoid use in patients with a history of severe respiratory disorders. - Monitor for signs of dependence or abuse, especially in individuals with alcohol use disorder. - Counsel patients about the potential for next‑day sedation and advise against operating machinery. - Review concomitant medications that depress the central nervous system.

Clomethiazole can interact with other substances that affect the central nervous system or hepatic metabolism, potentially altering its efficacy or safety profile.

Avoid: - Concurrent use with other sedative‑hypnotics such as benzodiazepines, barbiturates, or opioids. - Alcohol consumption while taking Heminevrin. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) that may increase plasma levels. - Grapefruit juice, which can inhibit CYP3A4 and raise clomethiazole concentrations.

Use with caution: - CYP3A4 inducers (e.g., rifampicin, carbamazepine) that may reduce effectiveness. - Antidepressants that lower seizure threshold, such as tricyclics. - Antihistamines or antihypertensives that may enhance sedative effects. - CNS depressants such as antihistamines, antipsychotics, or muscle relaxants may potentiate sedation. - Patients with cardiac conduction abnormalities should be monitored when combined with drugs that affect QT interval.